PubMed COVID-19 Clinical Care
38501 - 38510 of 50647 results found
Recent development of nanotechnology-empowered antigen assay methods for the control of infectious diseases
Description
The global spread of air-borne diseases, such as Covid-19 caused by the new coronavirus (SARS-CoV-2), has significantly impacted public health and economic development worldwide. Accurate and rapid detection of pathogens is the key to controlling the
Comparison of requirements for clinical study of SARS-CoV-2 antigen test kits in China, the USA and Europe
Description
Aims: This study was designed to analyze the requirements for clinical trials of SARS-CoV-2 antigen testing to explore the rationality and scientific rigor of clinical trials. Methods: The guidelines for the listing of SARS-CoV-2 antigen tests were
Unintended consequences of implementing non-pharmaceutical interventions for the COVID-19 response in Africa: experiences from DRC, Nigeria, Senegal, and Uganda
Description
CONCLUSION: Despite achieving pandemic control, the stringent NPIs had several negative and few positive unintended consequences. Governments need to balance the negative and positive consequences of NPIs by anticipating and instituting measures that
Threshold conditions for curbing COVID-19 with a dynamic zero-case policy derived from 101 outbreaks in China
Description
By 31 May 2022, original/Alpha, Delta and Omicron strains induced 101 outbreaks of COVID-19 in mainland China. Most outbreaks were cleared by combining non-pharmaceutical interventions (NPIs) with vaccines, but continuous virus variations challenged
A real-world data validation of the value of early-stage SIR modelling to public health
Description
Performance of Susceptible-Infected-Recovered (SIR) model in the early stage of a novel epidemic may be hindered by data availability. Additionally, the traditional SIR model may oversimplify the disease progress, and knowledge about the virus and
An interaction-based drug discovery screen explains known SARS-CoV-2 inhibitors and predicts new compound scaffolds
Description
The recent outbreak of the COVID-19 pandemic caused by severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) has shown the necessity for fast and broad drug discovery methods to enable us to react quickly to novel and highly infectious
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated with AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
Description
CONCLUSION: Symptomatic COVID-19 breakthrough cases in PROVENT were not due to resistance-associated substitutions in AZD7442 binding sites or lack of AZD7442 exposure.
Public trust is earned: Historical discrimination, carceral violence, and the COVID-19 pandemic
Description
CONCLUSIONS: Among Black respondents, lower satisfaction with the George Floyd death investigation was associated with lowered levels of trust in pharmaceutical companies, some government officials, and administrators; it was not associated with the
